source
- 'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrandNovo CEO Mike Doustdar—tapped to breathe new life into the Danish drugmaker last year after losing GLP-1 marketing ground to chief rival Eli Lilly—isn’t one to make changes for the sake of change.
- Biopharma workers increasingly postpone retirement, poll shows 52% plan to stay longerBiopharma professionals are rethinking retirement, with a BioSpace LinkedIn poll indicating that 52% expect to retire later than originally planned. Overall, 63% of respondents said they have chang…